መነሻ › አናፕላስቲክ ላርጅ-ሴል ሊምፎማ › New York
በNew York ለአናፕላስቲክ ላርጅ-ሴል ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች
ለአናፕላስቲክ ላርጅ-ሴል ሊምፎማ የሚደረጉ 5 ጥናቶች በNew York ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በNew York ውስጥ ያሉ ከተሞች
Official study text (English)
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- University of Rochester, Rochester
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06724237A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ26 ሜይ 2026 · NCT07001384A Registry for People With T-cell Lymphoma
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Weill Cornell Medical Center (Data Collection Only), New York
- እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT05978141Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
- New York Medical College, Valhalla
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ1 እስከ 39 · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT07013565ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።